



**The Cord Blood Forum &  
California Blood Bank Society**  
*proudly present*

**THE 6TH ANNUAL INTERNATIONAL UMBILICAL  
CORD BLOOD TRANSPLANTATION SYMPOSIUM**  
June 6-7, 2008 | Los Angeles, California USA

## Scientific Program

### Thursday, June 5, 2008

<b>Noon- 7:00 PM</b>	Registration
<b>6:00 - 8:00 PM</b>	Welcome Wine and Cheese Reception for all Attendees and Exhibitors- Poolside

### Friday, June 6, 2008

<b>7:00-8:00 AM</b>	<b>BREAKFAST in the Exhibits</b> (On site registration available)
<b>8:00-9:40 AM</b>	<b>SESSION I:        Transplantation of Adults; Double Cord Blood Transplants; Reduced Intensity Cord Blood Transplants</b>
	<b>Chairpersons:     Joseph Antin, M.D.                           John Wagner, M.D.</b>
<b>8:00 - 8:20 AM</b>	Progress in Umbilical Cord Blood Transplantation "From Zero to 10,000" John Wagner, MD, University of Minnesota, Minneapolis, MN
<b>8:20 - 8:35 AM</b>	Double Cord Blood Transplants – State of the Art. Claudio Brunstein, M.D., University of Minnesota, Minneapolis, MN
<b>8:35 - 8:50 AM</b>	CD34+ viability is a critical determinant of the engraftment potential of UCB in double unit transplantation. Machi Scaradavou, M.D., Memorial Sloan-Kettering Cancer Center, New York, NY
<b>8:50 - 9:05 AM</b>	Double UCBT with reduced intensity conditioning and Sirolimus-based GVHD prophylaxis. Joseph Antin, M.D., Dana-Farber Cancer Institute, Boston, MA
<b>9:05 - 9:20 AM</b>	Unrelated UCBT after reduced intensity conditioning in adults with hematologic malignancies - Combined data of Eurocord and University of Minnesota. Vanderson Rocha, M.D., Hôpital Saint-Louis, Paris, France
<b>9:20 - 9:40 AM</b>	"Targeted" Panel Discussion Moderators: Dr. Antin, Dr. Wagner Panelists: Antin, Brunstein, Rocha, Scaradavou, Wagner "Target Questions"
	<ol style="list-style-type: none"> <li>1. How can we determine if double cord blood transplants are superior to single cord transplants?</li> <li>2. What are the current indications for double cord transplants?</li> <li>3. What strategies can be used to select double cords for transplantation to a single patient?</li> <li>4. Is GVHD increased in double cord blood transplants?</li> <li>5. How do the GVHD incidence, severity and responsiveness to treatment compare with</li> </ol>

- PBSC and BMT transplants?
6. What is the potency of GVL after RIC. i.e., what is the efficacy of RIC UCBT In different diseases?
  7. What are the optimal preparative regimens and GVHD prevention regimens for reduced-intensity UCBT?

**AND:** Written questions from attendees (to be submitted at the Symposium)

**9:40 - 10:00 AM**      **SESSION II:      Honoring the basic scientists and clinicians who were pioneers in development of umbilical cord blood transplantation on the 20th anniversary of the first cord blood transplant.**

Introduced by UCB transplant recipients Matthew Farrow (recipient of the world's first CBT), Steven Sprague and Jill Anderson.

**10:00 - 10:30 AM**      **COFFEE BREAK in the Exhibits**

**10:30 - 11:50 AM**      **SESSION III:      Cord Blood Selection, Processing and Infusion**

**Chairpersons:      Eliane Gluckman, M.D.**  
**Juliet Barker, M.B.B.S.**

**10:30 - 10:45 AM**      Donor Selection in UCBT. Eliane Gluckman. M.D., Hôpital Saint-Louis, Paris, France.

**10:45 - 11:00 AM**      The dose-match interaction in UCB transplantation: An analysis of the impact of cell dose and HLA-match on the DFS of 989 patients transplanted with single units for hematologic malignancy. Juliet Barker, M.B.B.S., Memorial Sloan-Kettering Cancer Center, New York, NY

**11:00 - 11:15 AM**      Post thaw CFUs and other graft parameters that predict engraftment post-UCBT.  
Joanne Kurtzberg, M.D., Duke University, Durham, NC

**11:15 - 11:30 AM**      Is there more to cord blood units than cell dose?  
Robert Chow, M.D., StemCyte Cord International Blood Center, Covina, CA

**11:30 - 11:50 AM**      "Targeted" Panel Discussion  
Moderators: Dr. Barker, Dr. Gluckman  
Panelists: Barker, Chow, Gluckman, Kurtzberg  
"Target Questions"

1. How does one balance cell dose and HLA match in unit selection?
2. How can an individual transplant center incorporate results of CFU and CD34+ assays performed on the UCB product post-thaw into their clinical practice?
3. Are cell doses described as pre-cryopreservation or pre-infusion?
4. Is washing of units advisable?

**AND:** Written questions from attendees (to be submitted at the Symposium)

**11:50 AM - 1:00 PM**      **LUNCH in the Exhibits**

**1:00 - 2:40 PM**      **SESSION IV:      Overcoming Barriers to Transplantation - Facilitating the Search for a Cord Blood Unit**

**Chairpersons:      Richard Champlin, M.D.**  
**Dennis Confer, M.D.**

**1:00 - 1:15 PM**      Trials and tribulations of the cord blood search process. Life from the perspective of the search coordinator.  
Michele Alvarez, Transplant Coordinator, MD Anderson Cancer Center, Houston, TX

**1:15 - 1:35 PM**      Evolution of the cord blood search process: Toward a better search.  
Dennis Confer. M.D., National Marrow Donor Program, Minneapolis, MN

**1:35 - 1:55 PM**      Why patients with an indication for transplantation do not receive a transplant.  
Richard Champlin, M.D., MD Anderson Cancer Center, Houston, TX

**1:55 - 2:15 PM**      Referring physicians attitudes toward transplantation.  
Philip McCarthy, M.D., Roswell Park Cancer Institute, Buffalo, NY

**2:15 - 2:40 PM**      "Targeted" Panel Discussion  
Moderator: Dr. Champlin

Panelists: Alvarez, Champlin, Confer, McCarthy

"Target Questions"

1. What are the major causes of under-utilization of HSCT in general and UCBs in particular?
2. Are the indications for HSCT generally well defined?
3. When should a transplant physician search for a cord blood unit?
4. What is the optimal mechanism by which to search for a CB unit?
5. Can improvement in timeliness of referrals result in improved outcomes?

**AND:** Written questions from attendees (to be submitted at the Symposium)

**2:40 - 3:00 PM**

**COFFEE BREAK in the Exhibits**

**3:00 - 4:00 PM**

**SESSION V: Biology of Hematopoietic Cells**

**Chairperson: Hal Broxmeyer, Ph.D.**

3:00 - 3:20 PM

Influence of CD26 on cytokines and chemokines involved in proliferation, survival and movement of hematopoietic stem and progenitor cells.

Hal Broxmeyer, Ph.D., Indiana University School of Medicine, Indianapolis, IN

3:20 - 3:40 PM

E-type prostaglandins - multiple effects on hematopoiesis.

Louis Pelus, Ph.D., Indiana University School of Medicine Indianapolis, IN.

3:40 - 4:00 PM

The role of the nervous system in hematopoiesis.

Paul S. Frenette, M.D., Mount Sinai School of Medicine, New York, NY.

**4:00 PM**

**ADJOURN**

## **Saturday, June 7, 2008**

**7:00-8:00 AM**

**BREAKFAST in the Exhibits** (Registration desk will be open for single-day registrations)

**8:00 AM - NOON**

**SESSION VI: Basic Science and Clinical Studies Addressing Obstacles to Successful UCBT**

**Chairpersons: John Wagner, M.D.  
Kent Christopherson, Ph.D.**

8:00 - 8:20 AM

Introduction to the obstacles in UCB transplantation, and the basic science approaches to overcoming these obstacles; Characterization of engraftment after UCBT.

John Wagner, M.D., University of Minnesota, Minneapolis, MN

### Strategies to Improve Engraftment

8:20 - 8:40 AM

Strategies to improve homing.

Kent Christopherson, Ph.D., Rush University Medical Center, Chicago, IL

8:40 - 9:00 AM

Fucosylation of cord blood CD34+ cells.

Patrick Zweidler-McKay, M.D., Ph.D., MD Anderson Cancer Center, Houston, TX

9:00 - 9:20 AM

An ALDH augmentation trial which demonstrated enhancement of engraftment.

Joanne Kurtzberg, M.D., Duke University, Durham, NC

**9:20 - 9:40 AM**

**COFFEE BREAK in the Exhibits**

**9:40 AM - NOON**

**SESSION VI Immune Reconstitution, Opportunistic Infections and GVHD (continued)**

9:40 - 10:00 AM

GVHD in UCBT

Daniel Weisdorf, M.D., University of MN, Minneapolis, MN

10:00 - 10:20 AM

Chronic graft-versus-host disease following unrelated donor vs. UCB transplants: higher response rate in recipients of umbilical cord blood.

Mukta Arora, M.D., University of MN, Minneapolis, MN

10:20 - 10:40 AM

Biology of Immune Reconstitution.

Bruce Blazar, M.D., University of MN, Minneapolis, MN

10:40 - 11:00 AM	Characterization of immune recovery and its relevance regarding opportunistic infections after UCBT. Paul Szabolcs, M.D., Duke University, Durham, NC
11:00 - 11:20 AM	Genetic modification of cord blood T cells for anti-leukemic activity. Gianpietro Dotti, M.D., Baylor College of Medicine, Houston, Texas
11:20 - NOON	"Targeted" Panel Discussion Moderators: Dr. Wagner, Dr. Christopherson, Dr. Veneris Panelists: Arora, Blazar, Christopherson, Dotti, Kurtzberg, Szabolcs, Wagner, Weisdorf, Zweidler-McKay  "Target Questions"  <ol style="list-style-type: none"> <li>1. What is the mechanism of retained GVL in UCBT given GVHD is less severe?</li> <li>2. How significant are the reports of increased GVHD after peripheral blood stem cell transplants?</li> <li>3. Is acute and chronic GVHD more responsive to therapy after UCBT than after unrelated donor BMT or PBSC?</li> <li>4. Are cellular therapies to improve engraftment and immune recovery nearing clinical application?</li> </ol> <p><b>AND:</b> Written questions from attendees (to be submitted at the Symposium)</p>
<b>NOON - 1:15 PM</b>	<b>LUNCH in the Exhibits</b>
<b>1:15 - 3:00 PM</b>	<b>SESSION VII      Transplantation Immunology</b>  <b>Chairpersons:      Chang H. Kim, Ph.D</b> <b>                                 Jan Nolta, Ph.D.</b>
1:15 - 1:35 PM	Umbilical cord blood cytotoxic T cells. Jeffrey Miller, M.D., University of MN, Minneapolis, MN
1:35 - 1:55 PM	Inflammatory cytokine induced immunosuppression in mesenchymal stem cells. Yufang Shi, DVM, Ph.D., Robert Wood Johnson Medical School, Piscataway, NJ
1:55 - 2:15 PM	Liver engraftment by transplanted human progenitor cells with high aldehyde dehydrogenase activity in a novel model, NOD/SCID/MPSVII mice. Jan Nolta, Ph.D., University of California at Davis, Davis, CA
2:15 - 2:35 PM	Chemokine receptors and migration of cord blood-derived regulatory T cells. Chang H. Kim, Ph.D., Purdue Cancer Center, West Lafayette, IN
2:35 - 3:00 PM	Panel Discussion Moderators: Dr. Kim, Dr. Nolta Panelists: Kim, Nolta, Shi
<b>3:00 - 3:20 PM</b>	<b>COFFEE BREAK in the Exhibits</b>
<b>3:20 - 5:00 PM</b>	<b>SESSION VIII      Current Issues in Cord Blood Banking</b>  <b>Chairpersons:      Richard Champlin, M.D.</b> <b>                                 Dennis Confer, M.D.</b>
3:20 - 3:45 PM	A summary review: Cord blood banking - What is the state of the art?" Pablo Rubinstein, M.D., New York Cord Blood Center, New York, NY
3:45 - 4:15 PM	Progress in implementation of the Stem Cell Therapeutic and Research Act of 2005: a report from the Health Resources Services Administration (HRSA). Robert Baitty, M.P.P., HRSA, Rockville, MD
4:15 - 4:45 PM	The Food and Drug Administration and UCB banking and transplantation. Ellen Lazarus, M.D., US FDA, Rockville, MD
4:45 - 5:00 PM	Panel Discussion Moderator: Dr. Champlin, Dr. Confer Panelists: Baitty, Lazarus, Rubinstein
<b>5:00 PM</b>	<b>ADJOURN</b>